| Literature DB >> 27708058 |
Kimberly A Dowd1, Sung-Youl Ko2, Kaitlyn M Morabito2, Eun Sung Yang2, Rebecca S Pelc1, Christina R DeMaso1, Leda R Castilho3, Peter Abbink4, Michael Boyd4, Ramya Nityanandam4, David N Gordon1, John Robert Gallagher5, Xuejun Chen2, John-Paul Todd2, Yaroslav Tsybovsky6, Audray Harris5, Yan-Jang S Huang7, Stephen Higgs7, Dana L Vanlandingham7, Hanne Andersen8, Mark G Lewis8, Rafael De La Barrera9, Kenneth H Eckels9, Richard G Jarman10, Martha C Nason11, Dan H Barouch4, Mario Roederer2, Wing-Pui Kong2, John R Mascola2, Theodore C Pierson12, Barney S Graham13.
Abstract
Zika virus (ZIKV) was identified as a cause of congenital disease during the explosive outbreak in the Americas and Caribbean that began in 2015. Because of the ongoing fetal risk from endemic disease and travel-related exposures, a vaccine to prevent viremia in women of childbearing age and their partners is imperative. We found that vaccination with DNA expressing the premembrane and envelope proteins of ZIKV was immunogenic in mice and nonhuman primates, and protection against viremia after ZIKV challenge correlated with serum neutralizing activity. These data not only indicate that DNA vaccination could be a successful approach to protect against ZIKV infection, but also suggest a protective threshold of vaccine-induced neutralizing activity that prevents viremia after acute infection.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27708058 PMCID： PMC5304212 DOI： 10.1126/science.aai9137
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728